Burc Barin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11421877/publications.pdf

Version: 2024-02-01

361413 580821 1,709 25 25 20 citations h-index g-index papers 25 25 25 2079 docs citations all docs times ranked citing authors

#	Article	IF	CITATIONS
1	Influenza Among Young Children in Bangladesh: Clinical Characteristics and Outcomes From a Randomized Clinical Trial. Clinical Infectious Diseases, 2017, 65, 1914-1920.	5.8	3
2	First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. Journal of Infectious Diseases, 2017, 215, 95-104.	4.0	38
3	Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. The Lancet Global Health, 2016, 4, e946-e954.	6.3	46
4	Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16061.	4.1	39
5	A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS ONE, 2015, 10, e0125954.	2.5	31
6	Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons. PLoS ONE, 2015, 10, e0135882.	2.5	10
7	Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. AIDS and Behavior, 2015, 19, 794-801.	2.7	39
8	Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. Aids, 2015, 30, 1.	2.2	47
9	Best Single Time Point Correlations With AUC for Cyclosporine and Tacrolimus in HIV-Infected Kidney and Liver Transplant Recipients. Transplantation, 2014, 97, 702-707.	1.0	18
10	Acceptability and Feasibility of Repeated Mucosal Specimen Collection in Clinical Trial Participants in Kenya. PLoS ONE, 2014, 9, e110228.	2.5	8
11	Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV‹ infected liver and kidney transplant recipients. Biopharmaceutics and Drug Disposition, 2013, 34, 442-451.	1.9	29
12	Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial. PLoS ONE, 2013, 8, e74314.	2.5	69
13	Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Current Opinion in Oncology, 2012, 24, 517-521.	2.4	26
14	Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Human Vaccines and Immunotherapeutics, 2012, 8, 630-638.	3.3	4
15	Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients. Surgery, 2012, 152, 376-381.	1.9	21
16	Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers. PLoS ONE, 2012, 7, e33103.	2.5	131
17	A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2012, 7, e41936.	2.5	74
18	Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transplantation, 2012, 18, 716-726.	2.4	195

#	Article	IF	CITATION
19	A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus. AIDS Research and Human Retroviruses, 2010, 26, 933-942.	1.1	36
20	MELD Score Is an Important Predictor of Pretransplantation Mortality in HIV-Infected Liver Transplant Candidates. Gastroenterology, 2010, 138, 159-164.	1.3	77
21	Outcomes of Kidney Transplantation in HIV-Infected Recipients. New England Journal of Medicine, 2010, 363, 2004-2014.	27.0	493
22	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers. AIDS Research and Human Retroviruses, 2009, 25, 1107-1116.	1.1	53
23	Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 2008, 26, 2788-2795.	3.8	83
24	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine. AIDS Research and Human Retroviruses, 2008, 24, 873-880.	1.1	43
25	Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine, 2007, 25, 2120-2127.	3.8	96